New hope for endometrial cancer: Mo-Rez drug faces chemo in major trial
NCT ID NCT07286331
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large Phase 3 study tests a new drug called mocertatug rezetecan (Mo-Rez) against standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. About 600 participants will be randomly assigned to receive either Mo-Rez or one of two standard chemo drugs (paclitaxel or doxorubicin). The main goals are to see if Mo-Rez shrinks tumors better and delays cancer growth compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mocertatug rezetecan (Mo-Rez)
What this could lead to
If it works, this could offer a new treatment option for endometrial cancer that has stopped responding to platinum chemo and immunotherapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not work better than standard chemo and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••